Engineering Lymphatic Transport of Nanoparticles through Emulsion Polymerization
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide A library of lymphatic-targeting poly(propylene sulfide) nanoparticles (NPs) synthesized with copolymers of different properties at various concentrations was created. The effects of copolymer type and concentration on NP properties were explored, along with the transport behaviors of the NP formulations using in vitro assays that modeled diffusion through the skin interstitium and permeability across and uptake into lymphatic endothelial cells that predicted their in vivo lymphatic transport and uptake. By tuning the properties of the copolymer surfactants used during NP synthesis, both the NP characteristics and transport properties could be controlled, enabling the design of lymphatic-targeting drug delivery vehicles and imaging agents with varying behaviors.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Lymphatic System and Diseases · Advancements in Transdermal Drug Delivery · Noise Effects and Management
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Parker H. Petit Institute for Bioengineering and Bioscience
Georgia Institute of Technology
School of Chemical and Biomolecular Engineering
George W. Woodruff School of Mechanical Engineering
Wallace H. Coulter Department of Biomedical Engineering
Georgia Institute of Technology and Emory University
Winship Cancer Institute
Emory University
Funding
Fulbright Association · National Science Foundation Graduate Research Fellowship Program · National Cancer Institute · Shurl and Kay Curci Foundation
References (48)
Show source-provided references
1. 10.1016/j.coche.2014.11.00310.1016/j.coche.2014.11.003 ↗
2. 10.1038/s41578-019-0110-710.1038/s41578-019-0110-7 ↗
3. 10.1111/imr.1239910.1111/imr.12399 ↗
4. 10.1016/j.semcdb.2014.11.01210.1016/j.semcdb.2014.11.012 ↗
5. 10.1158/2326-6066.CIR-14-0019-T10.1158/2326-6066.CIR-14-0019-T ↗
6. 10.1016/j.biomaterials.2013.10.00310.1016/j.biomaterials.2013.10.003 ↗
7. 10.1016/j.jconrel.2023.10.00210.1016/j.jconrel.2023.10.002 ↗
8. 10.4110/in.2022.22.e910.4110/in.2022.22.e9 ↗
9. 10.1172/JCI12092310.1172/JCI120923 ↗
10. 10.2458/lymph.463810.2458/lymph.4638 ↗
11. 10.1007/BF0298724410.1007/BF02987244 ↗
12. 10.1016/S0748-7983(97)92885-710.1016/S0748-7983(97)92885-7 ↗
13. 10.3390/pharmaceutics1412275210.3390/pharmaceutics14122752 ↗
14. 10.1016/j.addr.2020.10.00410.1016/j.addr.2020.10.004 ↗
15. 10.1016/j.smim.2021.10153410.1016/j.smim.2021.101534 ↗
16. 10.1021/acs.accounts.0c0026010.1021/acs.accounts.0c00260 ↗
17. 10.1101/2022.06.02.4945510.1101/2022.06.02.49455 ↗
18. 10.1016/j.actbio.2022.03.05410.1016/j.actbio.2022.03.054 ↗
19. 10.1023/A:101211753144810.1023/A:1012117531448 ↗
20. 10.1126/sciadv.abd713410.1126/sciadv.abd7134 ↗
21. 10.1039/D4BM00910J10.1039/D4BM00910J ↗
22. 10.1021/la047804310.1021/la0478043 ↗
23. 10.1007/s00396-017-4141-610.1007/s00396-017-4141-6 ↗
24. 10.1021/acs.macromol.2c0180110.1021/acs.macromol.2c01801 ↗
25. 10.1021/la00024a01610.1021/la00024a016 ↗
26. 10.1007/s13404-011-0015-810.1007/s13404-011-0015-8 ↗
27. 10.1002/adma.20070197510.1002/adma.200701975 ↗
28. 10.1073/pnas.101838210810.1073/pnas.1018382108 ↗
29. 10.1002/anie.20080352610.1002/anie.200803526 ↗
30. 10.1007/s12195-022-00727-x10.1007/s12195-022-00727-x ↗
31. 10.1002/adhm.20230010510.1002/adhm.202300105 ↗
32. 10.1016/j.ijpharm.2023.12368810.1016/j.ijpharm.2023.123688 ↗
33. 10.1016/j.jconrel.2020.09.04210.1016/j.jconrel.2020.09.042 ↗
34. 10.1021/acs.biomac.0c0076910.1021/acs.biomac.0c00769 ↗
35. 10.1038/s41467-022-29121-x10.1038/s41467-022-29121-x ↗
36. 10.1016/j.jcis.2005.12.00910.1016/j.jcis.2005.12.009 ↗
37. 10.1021/bc900444310.1021/bc9004443 ↗
38. 10.1063/1.499992510.1063/1.4999925 ↗
39. 10.1101/2021.03.07.43429810.1101/2021.03.07.434298 ↗
40. 10.1126/sciadv.abq043510.1126/sciadv.abq0435 ↗
41. 10.3390/pharmaceutics1112067110.3390/pharmaceutics11120671 ↗
42. 10.2741/E10210.2741/E102 ↗
43. 10.1002/marc.20030004810.1002/marc.200300048 ↗
44. 10.1038/s41565-020-0679-410.1038/s41565-020-0679-4 ↗
45. 10.1007/s10856-012-4571-010.1007/s10856-012-4571-0 ↗
46. 10.1021/acs.nanolett.0c0375610.1021/acs.nanolett.0c03756 ↗
47. 10.1007/s10856-009-3746-910.1007/s10856-009-3746-9 ↗
48. 10.1146/annurev.immunol.20.100301.06482810.1146/annurev.immunol.20.100301.064828 ↗